Strain variation among and antifungal susceptibilities of isolates of Candida krusei

Journal of Clinical Microbiology

Volumn 34, Issue 7, 1996, Pages 1856-1858

  Berrouane, Y F ^a,b   Hollis, R J ^a   Pfaller, M A ^a  

^a UNIVERSITY OF IOWA   (United States)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; ITRACONAZOLE; RESTRICTION ENDONUCLEASE;

ARTICLE; CANDIDA KRUSEI; DRUG SENSITIVITY; ELECTROPHORESIS; GENOTYPE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE;

EID: 0029953314     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/jcm.34.7.1856-1858.1996     Document Type: Article

References (21)

1. Carlotti, A., R. Grillot, A. Couble, and J. Villard. 1994. Typing of Candida krusei clinical isolates by restriction endonuclease analysis and hybridization with CkF1,2 DNA probe. J. Clin. Microbiol. 32:1691-1699.
2. Goldman, M., J. C. Pottage, and D. C. Weaver. 1993. Candida krusei fungemia: report of four cases and review of the literature. Medicine (Baltimore) 72:143-150.
3. Iwen, P. C., D. M. Kelly, E. C. Reed, and S. H. Hinrichs. 1995. Invasive infection due to Candida krusei in immunocompromised patients not treated with fluconazole. Clin. Infect. Dis. 20:342-347.
4. McQuillen, D. P., B. S. Zingman, F. Meunier, and S. M. Levitz. 1992. Invasive infections due to Candida krusei: report of ten cases of fungemia that include three cases of endophthalmitis. Clin. Infect. Dis. 14:472-478.
5. Merz, W. G., J. E. Karp, D. Schron, and R. Saral. 1986. Increased incidence of fungemia caused by Candida krusei. J. Clin. Microbiol. 24:581-584.
6. Morace, G., M. Sanguinetti, L. Pagano, and B. Posteraro. 1994. Epidemiological characterization of Candida krusei clinical isolates using molecular techniques. J. Mycol. Med. 4:191-195.
7. National Committee for Clinical Laboratory Standards. 1992. Reference method for broth dilution antifungal susceptibility testing for yeasts. Proposed standard M27-P. National Committee for Clinical Laboratory Standards, Villanova, Pa.
8. Pfaller, M. A. 1996. Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Clin. Infect. Dis. 22(Suppl. 2):589-594.
9. Pfaller, M. A., M. Bale, B. Buschelman, M. Lancaster, A. Espinel-Ingroff, J. H. Rex, M. G. Rinaldi, C. R. Cooper, and M. R. McGinnis. 1995. Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine. J. Clin. Microbiol. 33:1104-1107.
10. Pfaller, M. A., and A. L. Barry. 1995. In vitro susceptibilities of clinical yeast isolates to three antifungal agents determined by the microdilution method. Mycopathologia 130:3-9
11. Pfaller, M. A., C. Grant, V. Morthland, and J. Rhine-Chalberg. 1994. Comparative evaluation of alternative methods for broth dilution susceptibility testing of fluconazole against Candida albicans. J. Clin. Microbiol. 32:506-509.
12. Pfaller, M. A., R. J. Hollis, and H. S. Sader. 1992. Chromosomal restriction fragment analysis by pulsed-field gel electrophoresis, p. 10.5.c.1-10.5.c.12. In H. D. Isenberg (ed.), Clinical microbiology procedures handbook. American Society for Microbiology, Washington, D.C.
13. Pfaller, M. A., S. A. Messer, and S. Coffmann. 1995. Comparison of visual and spectrophotometric methods of MIC endpoint determinations by using broth microdilution methods to test five antifungal agents, including the new triazole D0870. J. Clin. Microbiol. 33:1094-1097.
14. Pfaller, M. A., S. A. Messer, and R. J. Hollis. 1994. Strain delineation and antifungal susceptibilities of epidemiologically related and unrelated isolates of Candida lusitaniae. Diagn. Microbiol. Infect. Dis. 20:127-133.
15. Pfaller, M. A., S. A. Messer, and R. J. Hollis. 1995. Variations in DNA subtype, antifungal susceptibility, and slime production among clinical isolates of Candida parapsilosis. Diagn. Microbiol. Infect. Dis. 21:9-14.
16. Rex, J. H., M. A. Pfaller, A. L. Barry, P. W. Nelson, and C. D. Webb for the NIAID Mycoses Study Group and the Candidemia Study Group. 1995 Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. Antimicrob. Agents Chemother. 39:40-44.
17. Tenover, F. C., R. D. Arbeit, R. V. Goering, P. A. Mickelsen, B. E. Murray, D. H. Persing, and B. Swaminathan. 1995. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33:2233-2239.
18. Voss, A., M. A. Pfaller, R. J. Hollis, J. Rhine-Chalberg, and B. N. Doebbeling. 1995. Investigation of Candida aibicans transmission in a surgical intensive care unit cluster by using genomic DNA typing methods. J. Clin. Microbiol. 33:576-580.
19. Warren, N. G., and K. C. Hazen. 1995. Candida, Cryptococcus, and other yeasts of medical importance, p. 723-737. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 6th ed. American Society for Microbiology, Washington, D.C.
20. Wingard, J. R. 1995. Importance of Candida species other than C. aibicans as pathogens in oncology patients. Clin. Infect. Dis. 20:115-125.
21. Wingard, J. R., W. G. Merz, M. G. Rinaldi, T. R. Johnson, J. E. Karp, and R. Saral. 1991. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N. Engl. J. Med. 325:1274-1277.